Citations

Showing 10 of 107966 citations.

Minimally invasive surgical techniques for pancreatic cancer: ready for prime time?
Mesleh, Marc G., Stauffer, John , Asbun, Horacio J. , A Stauffer, John

Mayo Clinic

Journal of Hepato-Biliary-Pancreatic Sciences | April 16, 2013 | Volume: 20 | Issue: 6 | Pages: 578-582

10.1007/s00534-013-0614-2 | PMID 23591745 Get It

AbstractBackgroundMinimally invasive surgical techniques for pancreatic cancer are being applied with increasing frequency. With support of the literature, the location of the tumor within the pancreas is the factor which determines if these techniques can be safely used routinely by pancreatic surgeons.MethodsLiterature supporting minimally invasive techniques for all types of resections for pancreatic cancer was reviewed.ResultsMultiple meta‐analysis regarding laparoscopic distal pancreatectomy all support the routine use of laparoscopy for these lesions. There are several case series describing the safety and efficacious use of laparoscopy in pancreaticoduodenectomy, and results have been promising in these highly specialized centers.ConclusionsThe location of the tumor within the pancreas remains the most critical factor in the use of laparoscopy as the standard of care. Lesions in the body and tail, which are readily resected with a distal or subtotal pancreatectomy should be performed laparoscopically unless there is a clear reason why not to do so. Lesions in the head of the pancreas have been shown to be removed safely and effectively with laparoscopy. However, the technical skills necessary and the ability to teach these to trainees are the limiting factors to widespread use. Further series are necessary to assess if the laparoscopic approach to pancreaticoduodenectomy will play a similar role as the one it plays in the surgical treatment for distal lesions.
Precision Oncology: An Overview
Garraway, Levi A. , Verweij, Jaap, Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | April 15, 2013 | Volume: 31 | Issue: 15 | Pages: 1803-1805

10.1200/jco.2013.49.4799 | PMID 23589545 Get It

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial
Smallridge, Robert C., Copland, John A. , Brose, Marcia S. , Wadsworth, J. Trad , Houvras, Yariv , Menefee, Michael E., Bible, Keith C. , Shah, Manisha H. , Gramza, Ann W., Klopper, Joshua , Marlow, Laura A. , Roemeling, Reinhard von, Heckman, Michael G. , Marlow, Laura

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 15, 2013 | Volume: 98 | Issue: 6 | Pages: 2392-2400

10.1210/jc.2013-1106 | PMID 23589525 Get It

Improved Resident Physician Confidence With Advance Care Planning After an Ambulatory Clinic Intervention
Tung, Ericka E. , Verdoorn, Brandon P. , Mauck, Karen F. , Post, Jason , Thomas, Matthew R. , Bundrick, John B., Jaeger, Thomas M. , Cha, Stephen S., Thomas, Kris G., Wieland, Mark L. , Cha, Stephen S.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | April 15, 2013 | Volume: 31 | Issue: 3 | Pages: 275-280

10.1177/1049909113485636 | PMID 23588577 Get It

Many primary care providers feel uncomfortable discussing end-of-life care. The aim of this intervention was to assess internal medicine residents’ advance care planning (ACP) practices and improve residents’ ACP confidence. Residents participated in a facilitated ACP quality improvement workshop, which included an interactive presentation and chart audit of their own patients. Pre- and postintervention surveys assessed resident ACP-related confidence. Only 24% of the audited patients had an advance directive (AD), and 28% of the ACP-documentation was of no clinical utility. Terminally ill patients (odds ratio 2.8, P < .001) were more likely to have an AD. Patients requiring an interpreter were less likely to have participated in ACP. Residents reported significantly improved confidence with ACP and identified important training gaps. Future studies examining the impact on ACP quality are needed.
Oxytocin and vasopressin
Benarroch, Eduardo E.

Mayo Clinic

Neurology | April 15, 2013 | Volume: 80 | Issue: 16 | Pages: 1521-1528

10.1212/wnl.0b013e31828cfb15 | PMID 23589638 Get It

Favorable Stage Distribution in the NELSON Trial
Midthun, David E. , Gould, Michael K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 15, 2013 | Volume: 187 | Issue: 8 | Pages: 792-793

10.1164/rccm.201302-0314ed | PMID 23586379 Get It

Management of unruptured intracranial aneurysms
Williams, Lindsy N., Brown, Robert D.

Mayo Clinic

Neurology Clinical Practice | April 15, 2013 | Volume: 3 | Issue: 2 | Pages: 99-108

10.1212/cpj.0b013e31828d9f6b | PMID 23914319 Get It

Targeting deregulated epigenetic control in cancer
Zaidi, Sayyed K. , Wijnen, André J. van , Lian, Jane B. , Stein, Janet L. , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | April 15, 2013 | Volume: 228 | Issue: 11 | Pages: 2103-2108

10.1002/jcp.24387 | PMID 23589100 Get It

AbstractCancer is a multifaceted disease that involves acquisition of genetic mutations, deletions, and amplifications as well as deregulation of epigenetic mechanisms that fine‐tune gene regulation. Key epigenetic mechanisms that include histone modifications, DNA methylation, and non‐coding RNA‐mediated gene silencing are often deregulated in a variety of cancers. Subnuclear localization of key proteins in the interphase nucleus and bookmarking of genes by lineage commitment factors in mitosis—a new dimension to epigenetic control of fundamental biological processes—is also modified in cancer. In this review, we discuss the various aspects of epigenetic control that are operative in a variety of cancers and their potential for risk assessment, early detection, targeted therapy, and personalized medicine. J. Cell. Physiol. 228: 2103–2108, 2013. © 2013 Wiley Periodicals, Inc.
Defining acceptable limits for the metrological traceability of specific measurands
Bais, Renze, Armbruster, Dave, Jansen, Rob, Klee, George G., Panteghini, Mauro , Passarelli, J, Sikaris, Ken

Mayo Clinic

Clinical Chemistry and Laboratory Medicine | April 15, 2013 | Volume: 51 | Issue: 5 | Pages: 973-979

10.1515/cclm-2013-0122 | PMID 23525873 Get It

Abstract Although manufacturers are compelled by the European IVD Directive, 98/79/EC, to have traceability of the values assigned to their calibrators if suitable higher order reference materials and/or procedures are available, there is still no equivalence of results for many measurands determined in clinical laboratories. The adoption of assays with metrological traceable results will have a significant impact on laboratory medicine in that results will be equivalent across different laboratories and different analytical platforms. The IFCC WG on Allowable Errors for Traceable Results has been formed to define acceptable limits for metrological traceability chains for specific measurands in order to promote the equivalence of patient results. These limits are being developed based on biological variation for the specific measurands. Preliminary investigations have shown that for some measurands, it is possible for manufacturers to assign values to assay calibrators with a measurement uncertainty that allows the laboratory enough combined uncertainty for their routine measurements. However, for other measurands, e.g., plasma sodium, current assays are too imprecise to fulfil limits based on biological variation. Although an alternative approach based on probability theory is being investigated, the most desirable approach would be for industry to improve measurement methods so that they meet clinical requirements.
Hydrogen Sulfide Signaling in the Gastrointestinal Tract
Linden, David R.

Mayo Clinic

Antioxidants & Redox Signaling | April 15, 2013 | Volume: 20 | Issue: 5 | Pages: 818-830

10.1089/ars.2013.5312 | PMID 23582008 Get It

Significance: The current literature regarding the effects of the gaseous signal molecule hydrogen sulfide (H 2 S) in the gastrointestinal system is reviewed. Bacterial, host and pharmaceutical-derived H 2 S are all considered and presented according to the physiological or pathophysiological effects of the gaseous signal molecule. These subjects include the toxicology of intestinal H 2 S with emphasis on bacterial-derived H 2 S, especially from sulfate-reducing bacteria, the role of endogenous and exogenous H 2 S in intestinal inflammation, and the roles of H 2 S in gastrointestinal motility, secretion and nociception. Recent Advances: While its pro- and anti-inflammatory, smooth muscle relaxant, prosecretory, and pro- and antinociceptive actions continue to remain the major effects of H 2 S in this system; recent findings have expanded the potential molecular targets for H 2 S in the gastrointestinal tract. Critical Issues: Numerous discrepancies remain in the literature, and definitive molecular targets in this system have not been supported by the use of competitive antagonism. Future Directions: Future work will hopefully resolve discrepancies in the literature and identify molecular targets and mechanisms of action for H 2 S. It is clear from the current literature that the long-appreciated relationship between H 2 S and the gastrointestinal tract continues to be strong as we endeavor to unravel its mysteries. Antioxid. Redox Signal . 20, 818–830.